ABVC BioPharma Receives Notice of Allowance from US Patent and Trademark Office for ABV-1504 Used to Treat Major Depressive Disorder (MDD)
08 November 2022 - 12:30AM
via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical
stage biopharmaceutical company developing therapeutic solutions in
oncology/hematology, CNS, and ophthalmology, today announced that
on October 20, 2022, it received a Notice of Allowance for ABV-1504
from the US Patent and Trademark Office.
The patent, entitled “Polygala Extract for the Treatment of
Major Depressive Disorder,” outlines a method for treating major
depressive disorder by oral administration of a composition,
ABV-1504, containing Radix Polygalae (Polygala
tenuifolia Willd). The polygala extract, designated PDC-1421,
is the key active ingredient in ABV-1504 which was orally
administered to healthy volunteers and proved to be safe and
well-tolerated for a daily dose from 380 mg to 3800 mg. The study
indicated that the drug can be administered chronically over at
least 25 days with the daily dose administered once per day, twice
per day, or three times per day, wherein each dose contains from
380 mg to 760 mg of the botanical extraction.
In addition to the United States, the patent was also filed in
China, Taiwan and under the Patent Cooperation Treaty (PCT). The
PCT patent application was published on January 27, 2022, and
subsequently was filed in Japan, Australia and with the European
Patent Office (EPO).
“The new patent substantially extends the existing patent life
of ABV-1504 to the year 2041 in the US,” said Dr. Howard
Doong, ABVC chief executive officer. “Furthermore, we expect the
patent will be granted in China, Taiwan, Japan, Australia and
European countries, all of which allows us to commercialize our CNS
drugs globally without generic product competition.”
The Antidepressant Drugs Market is valued at USD
13.69 Billion in 2018 and expected to reach USD
15.88 Billion by 2025 with the CAGR of 2.15% over the forecast
period. (https://brandessenceresearch.biz/Request)
About ABVC BioPharma
ABVC BioPharma is a clinical-stage biopharmaceutical company
with an active pipeline of six drugs and one medical device
(ABV-1701/Vitargus) under development. For its drug products, it is
focused on utilizing its licensed technology to conduct
proof-of-concept trials through Phase II of the clinical
development process at world-famous research institutions (such as
Stanford University, University of California at San Francisco, and
Cedars-Sinai Medical Center). For Vitargus, the company intends to
conduct the clinical trials through Phase III at various locations
throughout the globe.
Forward-Looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential,” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions, and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified, and, consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
product candidates on a commercial scale on our own, or in
collaboration with third parties; (ii) difficulties in obtaining
financing on commercially reasonable terms; (iii) changes in the
size and nature of our competition; (iv) loss of one or more key
executives or scientists; and (v) difficulties in securing
regulatory approval to proceed to the next level of the clinical
trials or to market our product candidates. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company’s filings with the Securities and Exchange Commission
(SEC), including the Company’s Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors are urged to read these
documents free of charge on the SEC’s website
at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Contact:
Leeds ChowCFOEmail: leedschow@ambrivis.com
ABVC BioPharma (NASDAQ:ABVC)
Historical Stock Chart
From Feb 2024 to Mar 2024
ABVC BioPharma (NASDAQ:ABVC)
Historical Stock Chart
From Mar 2023 to Mar 2024